1. Cell Cycle/DNA Damage Epigenetics NF-κB Apoptosis Metabolic Enzyme/Protease Immunology/Inflammation
  2. HDAC Keap1-Nrf2 Apoptosis Bcl-2 Family Caspase Reactive Oxygen Species
  3. Sulforaphane

Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties.

For research use only. We do not sell to patients.

Sulforaphane Chemical Structure

Sulforaphane Chemical Structure

CAS No. : 4478-93-7

Size Price Stock Quantity
5 mg USD 38 In-stock
10 mg USD 60 In-stock
25 mg USD 135 In-stock
50 mg USD 240 In-stock
100 mg USD 420 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 50 publication(s) in Google Scholar

Other Forms of Sulforaphane:

Top Publications Citing Use of Products

45 Publications Citing Use of MCE Sulforaphane

WB
IF

    Sulforaphane purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2021 Aug 7;174412.  [Abstract]

    Immunofluorescence histochemistry confirmes that Sulforaphane (SFN) treatment further increased Nrf2 and HO-1 expression in the dorsal horn of the spinal cord of CIBP rats.

    Sulforaphane purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2021 Aug 7;174412.  [Abstract]

    Western blotting analysis shows that CIBP can significantly induce the protein expression of Nrf2 and HO-1 in the spinal cord and that intrathecal administration of Sulforaphane (SFN) can further promoted the protein expression of Nrf2 and HO-1 protein.

    Sulforaphane purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jun 5;10(16):7319-7334.  [Abstract]

    The distribution of iNOS (green) and ARG-1 (red) in BMDMs according to immunofluorescence. Sulforaphane (SFN; 10 μM or 20 μM) decreases iNOS and increases ARG-1 levels.

    Sulforaphane purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jun 5;10(16):7319-7334.  [Abstract]

    Western blot detection of Nrf2, TLR4, IRF1, iNOS, and ARG-1 levels following Sulforaphane (SFN; 10 μM or 20 μM) treatment or Nrf2 upregulation/downregulation in BMDMs co-cultured with COM-stimulated TECs. SFN treatment activates Nrf2 expression, which then downregulates the expression of TLR4, IRF1, and iNOS and upregulates the expression of ARG-1.

    Sulforaphane purchased from MedChemExpress. Usage Cited in: Vascul Pharmacol. 2018 Oct;109:56-71.  [Abstract]

    A representative western blot analysis gel showing the reduces abundance of eNOS relative to GAPDH in tissues cultured under hyperglycaemic conditions (25 mM glucose: 25) versus either freshly isolated tissues (F, first lane on left) or tissues cultured under euglycaemic conditions (10 mM glucose: 10). The abundance of eNOS is preserved for tissues cultured in 25 mM glucose along with 1 μM Sulforaphane (25+S).
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties[1][2][3][4][5][6].

    IC50 & Target[1]

    HDAC

     

    Bax

     

    Caspase-3

     

    In Vitro

    Sulforaphane (0-30 μM) induces cell cycle arrest and apoptosis in a dose-dependent manner. Sulforaphane-induced cell cycle arrest is associated with an increase in the expression of cyclin A and B1[1].
    Sulforaphane (0-30 μM) inhibits the re-initiation of growth and decreases cell viability in HT29 cells, exhibiting lower toxicity towards differentiated cells[1].
    Sulforaphane (10 μM, 24 hours) pre-treatment reduces the number of apoptotic cells, decreases the expression of pro-apoptotic proteins (Bax, caspase-3, cytochrome c), and counteracts the increase in mitochondrial membrane potential induced by Doxorubicin (HY-15142A) (1 μM, 2 hours) in H9c2 cells[2]. Sulforaphane (10 μM, 2 or 24 hours) effectively reduces ROS production and cell apoptosis in H9c2 cells induced by Doxorubicin (1 μM, 2 or 24 hours) through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Western Blot Analysis[2]

    Cell Line: H9c2 cells
    Concentration: Sulforaphane: 10 μM; Doxorubicin: 1 μM
    Incubation Time: Sulforaphane: 2h; Doxorubicin: 2, 24h
    Result: Prevented the release of cytochrome c into the cytosol.
    Prevented the translocation of Bax into the cytosol.
    Attenuated the doxorubicin-induced increase in the levels of cleaved caspase-3.
    Induced a significant increase in HO-1 protein expression.
    Induced a significantly higher level of Nrf2 expression in the nucleus compared to the cytoplasm.

    Apoptosis Analysis[2]

    Cell Line: H9c2 cells
    Concentration: Sulforaphane: 10 μM; Doxorubicin: 1 μM
    Incubation Time: Sulforaphane: 2h; Doxorubicin: 24h
    Result: Protected the H9c2 cells against doxorubicin-induced cell death.
    Increased cell viability in a dose-dependent manner.
    Significantly reduced the number of apoptotic cells treated with Doxorubicin.

    RT-PCR[2]

    Cell Line: H9c2 cells
    Concentration: Sulforaphane: 10 μM; Doxorubicin: 1 μM
    Incubation Time: Sulforaphane: 2, 24h; Doxorubicin: 2, 24h
    Result: Induced heme oxygenase-1 (HO-1) mRNA expression in a dose-dependent manner.
    In Vivo

    Sulforaphane (13.3, 17.7, 26.6 mg/kg; Oral gavage; 5 days) is capable of inhibiting the formation of mammary tumors in female Sprague-Dawley rats following a single-dose treatment with DMBA (HY-W011845) (8 mg/mL)[3].
    Sulforaphane (13.3, 17.7, 26.6 mg/kg; Oral gavage; 5 days) can reduce the incidence, multiplicity, and weight of mammary tumors induced by DMBA (8 mg/mL) in female Sprague-Dawley rats, and delay their development[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Female Sprague-Dawley rat[3]
    Dosage: Sulforaphane: 13.3, 17.7, 26.6 mg/kg; DMBA (HY-W011845): 8 mg/mL
    Administration: Oral gavage; 5 days
    Result: Prevented the occurrence of tumors in a dose-dependent manner.
    Significantly reduced the incidence of tumors.
    Clinical Trial
    Molecular Weight

    177.29

    Formula

    C6H11NOS2

    CAS No.
    Appearance

    Liquid (Density: 1.17±0.1 g/cm3)

    Color

    Colorless to light yellow

    SMILES

    O=S(CCCCN=C=S)C

    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    -20°C, sealed storage, away from moisture and light

    *The compound is unstable in solutions, freshly prepared is recommended.

    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 62.5 mg/mL (352.53 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 5.6405 mL 28.2024 mL 56.4048 mL
    5 mM 1.1281 mL 5.6405 mL 11.2810 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (14.10 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (14.10 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: ≥ 50 mg/mL (282.02 mM); Clear solution

    • Protocol 2

      Add each solvent one by one:  0.5% CMC-Na/saline water

      Solubility: ≥ 50 mg/mL (282.02 mM); Clear solution

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *The compound is unstable in solutions, freshly prepared is recommended.

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.75%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 5.6405 mL 28.2024 mL 56.4048 mL 141.0119 mL
    5 mM 1.1281 mL 5.6405 mL 11.2810 mL 28.2024 mL
    10 mM 0.5640 mL 2.8202 mL 5.6405 mL 14.1012 mL
    15 mM 0.3760 mL 1.8802 mL 3.7603 mL 9.4008 mL
    20 mM 0.2820 mL 1.4101 mL 2.8202 mL 7.0506 mL
    25 mM 0.2256 mL 1.1281 mL 2.2562 mL 5.6405 mL
    30 mM 0.1880 mL 0.9401 mL 1.8802 mL 4.7004 mL
    40 mM 0.1410 mL 0.7051 mL 1.4101 mL 3.5253 mL
    50 mM 0.1128 mL 0.5640 mL 1.1281 mL 2.8202 mL
    60 mM 0.0940 mL 0.4700 mL 0.9401 mL 2.3502 mL
    80 mM 0.0705 mL 0.3525 mL 0.7051 mL 1.7626 mL
    100 mM 0.0564 mL 0.2820 mL 0.5640 mL 1.4101 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Sulforaphane
    Cat. No.:
    HY-13755
    Quantity:
    MCE Japan Authorized Agent: